Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 8 AND DEXTROSE 5 IN PLASTIC CONTAINER versus LIDOSITE TOPICAL SYSTEM KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 8 AND DEXTROSE 5 IN PLASTIC CONTAINER versus LIDOSITE TOPICAL SYSTEM KIT.
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER vs LIDOSITE TOPICAL SYSTEM KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses. It also has antiarrhythmic properties by decreasing automaticity in Purkinje fibers and suppressing ventricular arrhythmias.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses.
Intrathecal administration for spinal anesthesia: 50-100 mg (1.5-2 mL of 5% solution) as a single dose. For continuous epidural or peripheral nerve block, 0.8% solution with dextrose 5% is not typically used; refer to 1-2% lidocaine without dextrose for continuous infusion.
Apply up to 3 patches topically once daily for up to 12 hours per day. Maximum 3 patches (210 mg lidocaine) per day.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (adults); prolonged in heart failure (up to 5-8 hours) or hepatic impairment (up to 10-15 hours). Clinically, context indicates redistribution half-life ~8 minutes.
1.5-2 hours (terminal); prolonged in hepatic dysfunction or heart failure
Renal (metabolites: 4-hydroxyxylidine, glycylxylidide, monoethylglycinexylidide; <10% unchanged). Biliary/fecal negligible.
Renal (80-90% as metabolites, <10% unchanged), biliary/fecal (minor, <5%)
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic